Penumbra Inc (PEN): Results of Operations and Financial Condition
Penumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pen-63026xexhibit991.htm EX-99.1 Document Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the reported Q2 growth and margin, while also adjusting for the absence of full-year 2026 guidance due to the acquisition process.
Market read
Q2 financials support an improving operating profile, but the acquisition removes full-year guidance, increasing reliance on deal progress and regulatory risk.
What to watch
Net income fell vs prior-year quarter ($34.8M vs $45.3M) and the company highlighted risks that regulatory approvals may not be obtained, which can dominate near-term trading.
Background
Penumbra filed an 8-K with Q2 2026 results and noted it is pending acquisition by Boston Scientific (BSX).
Ticker impact
Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY) and disclosed it will not provide full-year 2026 guidance due to the pending BSX acquisition.
Near-term sentiment likely positive on growth and margin, but guidance absence and deal-close risk can cap upside and increase volatility.
The filing provides concrete quarterly financials (revenue, margins, operating income) and a specific forward-looking change (no full-year guidance) tied to the pending Boston Scientific acquisition.
Market effects
Thrombectomy device peers may see read-across on procedure demand and pricing/margin durability, but deal pendency reduces forward visibility for Penumbra specifically.
No explicit regional macro drivers beyond disclosed US vs international revenue growth rates.
Limited broader market impact; primarily company-specific and acquisition-related.
Counterpoint
The strong Q2 growth and margin could be partially offset by acquisition-related expense drag and uncertainty around deal timing, making the stock more sensitive to BSX deal headlines than fundamentals.
Key entities
- companyPenumbra, Inc.
NYSE-listed thrombectomy company reporting Q2 2026 results and acquisition-related guidance change.
- companyBoston Scientific Corporation
Buyer in the pending acquisition referenced as the reason Penumbra will not provide full-year 2026 guidance.
